Merus N.V. logo

Merus N.V. (MRUS)

Market Open
29 Jul, 15:39
NASDAQ (NMS) NASDAQ (NMS)
$
65. 16
-0.43
-0.66%
$
4.71B Market Cap
- P/E Ratio
0% Div Yield
114,879 Volume
-2.67 Eps
$ 65.59
Previous Close
Day Range
64.61 65.92
Year Range
33.19 67.25
Want to track MRUS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 1 days
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Merus (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.

Zacks | 1 year ago
Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

Merus N.V. is experiencing significant growth and entering a higher price territory, making the risk-reward less clear. The company's bispecific antibody, petosemtamab, showed promising results in a phase 2 study for head and neck squamous cell carcinoma. Merus' other bispecific antibody, zenocutuzumab, has a high chance of approval for NRG1-positive NSCLC and pancreatic cancer, with a decision expected later in 2024.

Seekingalpha | 1 year ago